

# ACCORD 2 Newsletter

ACCORD – a national Phase 2, CMO prioritised study funded by UKRI and supported by the NIHR to develop the next generation of drugs for COVID-19.

The drugs currently in trial are:

- **Bemcentinib** – AXL inhibitor which may prevent viral infection and lung inflammation
- **MEDI3506** – an anti-IL-33 monoclonal antibody
- **Acalabrutinib** – a Bruton's tyrosine kinase (BTK) inhibitor
- **Zilucoplan** – a complement C5 inhibitor that could block severe inflammatory responses

## Active ACCORD Sites

St Thomas', Guys, Wythenshawe and Manchester FT who opened on Arm 002 and have recently opened to 006 as well.

We wish you well with your recruitment.

## Recruitment Figures so far:

<b>Arm 002 Bemcentinib</b> -	<b>4</b>
<b>Arm 003 MEDI3506</b> -	<b>9</b>
<b>Arm 004 Acalabrutinib</b> -	<b>6</b>
<b>Arm 006 Zilucoplan</b> -	<b>5</b>



*Congratulations to Glenfield Hospitals on their recruitment this week.*



The ACCORD 2 committee are actively pursuing conversations regarding the provision of Point of Care (PoC) testing machines to those sites where the delivery team have shared it would aid recruitment. Further information will be cascaded as discussions progress.



The recent amendment is now at each site for respective issue of continuing C&C, please nudge your R&D colleagues if you have not yet received this.

Please note that tablets will be updated once all sites in the sub-protocol have issued their C&C, they will then "go down" for a time while the new PIS/ICF is uploaded.

Please liaise with your CRA re timeframes for your respective sub-protocols.

**Items to  
note:**

**Data Entry** – Procedures and/or tests that are only undertaken once as part of Screening / Baseline should only be entered into RAVE only once. Please do not duplicate information in the screen and baseline pages in eCRF.

**eConsent platform** – Please ensure the IWRS Screening number is used as the Study Subject number in the eConsent form.